Impetigo Market Report 2026

Impetigo Market Overview

• Impetigo market size has reached to $2.4 billion in 2025 • Expected to grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Skin Infections And Their Impact On The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Impetigo Market?

Impetigo is a highly contagious bacterial skin infection primarily caused by streptococcus pyogenes. It typically presents as red sores or blisters that break open, ooze, and form a yellowish-brown crust. The infection spreads easily through direct skin-to-skin contact or by touching contaminated surfaces. The main treatment types of impetigo are topical antibiotics, oral antibiotics, antiseptic soaks. Oral antibiotics are pills or liquid medicines taken by mouth to treat impetigo, typically used when the infection is more severe or widespread. The various causative pathogens include staphylococcus aureus, streptococcus pyogenes, other bacteria with various severity include mild, moderate, severe used by various patient age such as children, adults, elderly.

What Is The Impetigo Market Growth Forecast?

The impetigo market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising concern over antibiotic resistance, development of novel topical formulations, increasing healthcare access in emerging regions, growing focus on preventive dermatology, improved public health education on skin infections. Major trends in the forecast period include increasing preference for topical antibiotics over systemic therapy, rising focus on early diagnosis and rapid treatment initiation, growing demand for pediatric-specific impetigo treatments, increased emphasis on infection prevention and hygiene awareness, expansion of over-the-counter and outpatient treatment approaches.

Global Impetigo Market Segmentation

1) By Treatment Type: Topical Antibiotics, Oral Antibiotics, Antiseptic Soaks 2) By Causative Pathogen: Staphylococcus aureus, Streptococcus pyogenes, Other Bacteria 3) By Severity: Mild, Moderate, Severe 4) By Patient Age: Children, Adults, Elderly Subsegments: 1) By Topical Antibiotics: Mupirocin, Retapamulin, Fusidic Acid 2) By Oral Antibiotics: Cephalexin, Dicloxacillin, Clindamycin 3) By Antiseptic Soaks: Chlorhexidine, Hydrogen Peroxide, Potassium Permanganate

What Are The Drivers Of The Impetigo Market?

The rising prevalence of skin infections is expected to propel the growth of the impetigo market going forward. Skin infections refer to conditions where harmful microorganisms, like bacteria, viruses, fungi, or parasites, invade the skin and cause irritation, inflammation, or other symptoms. The rising skin infections are due to high antibiotic resistance, poor hygiene, climate change, weakened immune systems, and increased global travel. Impetigo treatment supports the management and resolution of the infection by targeting the bacterial pathogens, typically Streptococcus or Staphylococcus species, through the use of topical or oral antibiotics, which help reduce symptoms such as itching and discomfort, prevent the spread of the infection, and accelerate the healing process, ultimately minimizing the risk of complications and recurrence. For instance, in October 2023, according to the European Academy of Dermatology and Venereology (EADV), a Switzerland-based nonprofit professional medical organization in Europe, about 43% of EU citizens reported having at least one skin disease in the previous 12 months, with fungal skin infections ranked among the most common conditions. Therefore, the rising prevalence of skin infections is driving the growth of the impetigo industry. The improvement of healthcare facilities is expected to propel the growth of the impetigo market going forward. Healthcare facilities are establishments that offer medical care and services, such as hospitals, clinics, and diagnostic centers, to treat and support patients. Healthcare facilities are improving due to several factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Improvement of healthcare facilities supports the management and treatment of impetigo by enhancing access to specialized dermatological care, increasing the availability of effective treatment options, fostering better hygiene practices in healthcare settings to prevent the spread of infections, and facilitating early diagnosis and timely interventions, ultimately contributing to improved patient outcomes and reducing the burden of skin infections. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the improvement of healthcare facilities is driving the growth of the impetigo industry. The rise in healthcare spending is expected to propel the growth of the impetigo market going forward. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is attributed to aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports impetigo by driving demand for advanced therapeutic solutions, enabling investment in innovative treatments, and ensuring broader access to critical care products that improve patient outcomes. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare spending is driving the growth of the impetigo industry.

Key Players In The Global Impetigo Market

Major companies operating in the impetigo market are Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Galderma SA, Dr. Reddy's Laboratories Ltd., Leo Pharma A/S, Torrent Pharmaceuticals Ltd., Almirall S.A, Taro Pharmaceutical Industries Ltd., Cutanea Life Sciences Inc., InfectoPharm Arzneimittel und Consilium GmbH, NovaBay Pharmaceuticals Inc.

Regional Outlook

North America was the largest region in the impetigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Impetigo Market?

The impetigo treatment market consists of sales of non-bullous impetigo, and bullous impetigo. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Impetigo Market Report 2026?

The impetigo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the impetigo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.